Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia

Exclusion Criteria

• •1. Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease, which might confound assessment of safety outcomes.
• •2. Seizure disorder
• •3. Lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, as determined by the MINI
• •4. Current episode of major depression, as determined by the MINI
• •5. Active substance abuse or dependence within the past 6 months, as determined by the MINI
• •6. Delirium (as measured by the CAM)
• •7. Current inpatient hospitalization
• •8. Current regular use of cannabinoid products (\>1 use per month)
• •9. Positive urine screen for THC at the screening or baseline visit
• •10. Allergy to coconut
• •11. Participants taking strong inhibitors or inducers of CYP3A4 (e.g. fluconazole, fluoxetine, fluvoxamine, ticlopidine, St. John's Wort, etc.), CYP2C19 (ketoconazole, erythromycin, etc.), or anti-epileptic drugs